However, a phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with R/R AML and high-risk MDS still suggested insufficient evidence in clinical activity as expected in spite of well preclinical effect (125). Here, CD47 is linked to acute myeloid leukemia.